American Urological Association's Annual Meeting (AUA) | Conference

Avelumab Up Front Plus BSC Prolongs OS in Advanced Urothelial Carcinoma Over BSC Alone
May 25, 2022

The JAVELIN Bladder 100 trial demonstrated that avelumab plus best supportive care prolonged overall survival vs best supportive care alone for patients with advanced urothelial carcinoma.

Darolutamide Yields Positive, Long-Lasting Outcomes in nmCRPC With or Without Prior Local Therapy
May 24, 2022

Three year follow-up findings from a post hoc analysis of the phase 3 ARAMIS trial indicated that darolutamide maintained a survival benefit regardless of prior local therapy for patients with nonmetastatic castration-resistant prostate cancer.

Promising Safety and Efficacy Observed With Niraparib/Abiraterone Acetate Combination for HRR-Altered mCRPC
May 23, 2022

Adding niraparib to abiraterone acetate and prednisone improved efficacy and yielded tolerable safety for patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations.

Infigratinib Appears Active, Tolerable in Upper Tract Urothelial Carcinoma
May 22, 2022

Patients with upper tract urothelial carcinoma may benefit from treatment with oral FGFR1-3 inhibitor infigratinib.

Enzalutamide Plus ADT Yields Lasting Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer ± Prior Therapy
May 21, 2022

Findings from the phase 3 ARCHES trial highlighted a long-lasting survival improvement for patients with metastatic hormone-sensitive prostate cancer who were treated with enzalutamide plus androgen deprivation therapy regardless of whether they received prior local therapy.

Mark T. Fleming, MD, Talks Use of 18F-rhPSMA-7.3 for PET/CT in Recurrent Prostate Cancer
May 19, 2022

Mark T. Fleming, MD, spoke about how use of 18F-rhPSMA-7.3 for PET/CT scans in patients with recurrent prostate cancer bests conventional imaging.

18F-rhPSMA-7.3 Exhibits Greater Ability to Upstage Disease Vs Conventional Imagine in Recurrent Prostate Cancer
May 16, 2022

Superior post-scan disease upstaging in patients with recurrent prostate cancer was observed with 18F-rhPSMA-7.3 compared with conventional baseline imaging.

Overall Survival With Lutetium 177 May Be Impacted by Subsequent Therapies, Prognostic Risk Groups in mCRPC
October 10, 2021

The CALGB prognostic risk group and subsequent life-prolonging therapies could potentially impact overall survival in patients with metastatic castration-resistant prostate cancer who are receiving lutetium 177.

UGN-101 Results in a Long-Lasting Response in Low-Grade Upper Tract Urothelial Carcinoma
September 26, 2021

Patients with low-grade upper tract urothelial carcinoma achieved a long period of durable response after undergoing treatment with UGN-101.

Yoga May Promote Antitumor Immune Responses and Boost Quality of Life in Prostate Cancer
September 25, 2021

Yoga not only yields improvements in physical, mental, and sexual wellbeing, but it may also result in reduced inflammation and antitumor responses in men with prostate cancer.